Bristol-Myers Squibb (BMY)

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.

Bristol Myers Squibb (BMY) concluded the recent trading session at $48.66, signifying a -2.19% move from its prior day's close.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #18ICML--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi.

Stocks experienced significant volatility this year, which can sometimes make it challenging to keep a positive outlook. In times like these, it's worthwhile to remember that stock-market swings, even...

BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.

Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.

The Dividend Harvesting Portfolio hit a new all-time high, delivering a 26.95% return and $2,310.77 in forward annual dividend income. I continue to diversify across ETFs, REITs, CEFs, BDCs, and equit...

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025.

Bristol-Myers Squibb Company (NYSE:BMY ) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization O...